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ABSTRACT--In this issue of Oncogene, Albinet and colleagues have demonstrated a 
critical role of melanoma sphingosine kinase 1, which catalyses formation of sphingosine 1-
phosphate, in promoting the differentiation of fibroblasts into myofibroblasts.  The 
myofibroblast sphingosine kinase 1 then promotes the sphingosine 1-phosphate-dependent 
dissemination (metastasis) of melanoma cells via a sphingosine 1-phosphate receptor 3-
mediated mechanism.  These findings are of major significance because they provide a 
novel mechanism of interaction between melanoma and the microenvironment niche in 
promoting metastasis.  These studies therefore identify sphingosine 1-phosphate derived 
from myofibroblasts and melanoma cells as a novel target for therapeutic intervention. 
 
Sphingosine 1-phosphate (S1P) is a bioactive lipid that has been demonstrated to have an 
important role in cancer including the promotion of metastasis of tumour cells1.  Recently 
Ponnusamy et al.2 demonstrated that systemic S1P, produced by the host sphingosine kinase 1 
(SPHK1) rather than tumour-derived S1P, promotes lung colonisation/metastasis.  Thus, a 
reduction in systemic S1P inhibited TRAMP-induced prostate cancer growth in TRAMP+/+Sphk1-
/-
 mice or lung metastasis of a number of cancer cells in Sphk1-/- mice.  The loss of SPHK1 
promotes the expression of Brms1 (breast carcinoma metastasis suppressor 1).  Indeed, S1P 
binding to S1P receptor 2 (S1P2) reduces Brms1 expression in cancer cells.  The sequestration of 
systemic S1P using a novel anti-S1P monoclonal antibody also reduced lung metastasis and this 
was prevented by knockdown of Brms1 in the tumour cells2. These findings raise the question of 
the source of systemic S1P.  The major advance made by Albinet et al.3 in this issue of Oncogene 
is that the S1P derived from myofibroblasts in the tumour microenvironment might be a potential 
source of systemic S1P.  It has been well established that stromal cells functionally interact with 
tumour cells to promote aggressive metastatic cancer.  The stroma is principally composed of 
myofibroblasts (also known at tumour associated fibroblasts, TAF) which are derived from 
fibroblasts, homing fibrocytes and/or mesenchymal cells.  The TAFs secrete growth factors and 
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extracellular matrix and matrix metalloproteinases, which promote cancer progression.  Indeed, 
the dense fibrotic nature of melanoma is thought to be a consequence of myofibroblasts and poor 
prognosis is linked with the presence of these cells in the tumour.   
 
This then raises the question as to the role of the myofibroblasts within the context of S1P 
biology and melanoma dissemination.  In this regard, there is a substantial body of evidence 
demonstrating that S1P is involved in fibrosis; promoting differentiation of fibroblasts into 
myofibroblasts.  For instance, S1P increases the expression of SPHK1 and S1P1/3 which are 
increased in human fibrotic livers4.  In addition, siRNA knockdown of SPHK1 reduces TGFE1-
stimulated D-SMA and fibronectin expression in WI-38 human lung fibroblasts; a differentiation 
response that is mediated by S1P and S1P2/3 receptors5.  TGFE also increases SK1 expression in 
cardiac fibroblasts6.  In this case, S1P formed by SPHK1 is released from cardiac fibroblasts and 
stimulates collagen and D-SMA expression via an S1P2- and Rho kinase-dependent pathway in 
an autocrine manner6.   
 
Albinet et al.3 have connected SPHK1 expressed in melanoma with SPHK1 in myofibroblasts to 
provide a molecular explanation for the dissemination and growth of melanoma (Fig. 1).  These 
authors demonstrate that S1P metabolism is disrupted in melanoma cells.  For instance, the 
expression level of SPHK1 is substantially increased in melanoma compared with adjacent 
melanocytic nevus in patients.  Moreover, over-expression of WT BRAF or BRAFV600E 
constitutively active mutant in HEK 293 cells induced an increase in the expression of SPHK1 
and this is dependent on ERK activation. In addition, siRNA knockdown of BRAF in SKMel-28 
cells reduced ERK phosphorylation and SPHK1 expression.  These data are important as they 
link oncogenic BRAF, a major driver of melanoma with changes in SPHK1 expression.  The 
authors then used COLO829 melanoma cells, which are SPHK1 null to generate ectopic SPHK1 
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expressing COLO829 cells, and found that the migration of these cells was unaffected.  The lack 
of a role for SPHK1 in regulating melanoma migration was confirmed using SPHK1 silencing in 
A375 melanoma cells.  These surprising findings strongly support a model in which S1P formed 
by melanoma cells, where SPHK1 expression is increased, does not function in an autocrine 
manner to stimulate cell migration via S1P receptors.  In contrast, exogenous S1P did promote 
the migration of A375 cells via an S1P1/3-dependent mechanism.  However, using conditioned 
medium from SPHK1 expressing COLO829 cells (compared with COLO829 cells, SPHK1 null), 
Albinet et al.3 demonstrated the differentiation of skin fibroblasts into myofibroblasts with 
increased expression and release of MMP-2 and MMP-9, both of which are involved in 
melanoma cell invasion.  Conditioned medium from SPHK1 expressing COLO829 cells also 
increased the expression of SPHK1 in fibroblasts and this resulted in increased S1P release from 
these fibroblasts.  These findings were recapitulated in TAF compared with human dermal 
fibroblasts.  Therefore, S1P released from melanoma cells appears to promote a fibrotic response 
in the tumour microenvironment.  Significantly, conditioned medium from SPHK1 over-
expressing fibroblasts promote A375 melanoma migration, while a 50% knockdown of SPHK1 
in fibroblasts decreased melanoma migration.  The conditioned medium from SPHK1 over-
expressing fibroblasts also induced a 3-fold increase in S1P3 expression in melanoma cells, 
suggesting that the migratory response of these cells is mediated by this receptor.  These findings 
are in line with the observation that mice allografted with B16F10 melanoma exhibited 
substantial retardation of tumour progression upon anti-S1P antibody treatment7. 
 
Finally, Albinet et al.3 injected B16F10 murine melanoma cells into the dermis of wild-type or 
Sphk1-/- mice together with WT or Sphk1-/- dermal fibroblasts.  Melanoma growth was 
significantly reduced in Sphk1-/- syngenic mice.  Moreover, tumour volume and weight was 
reduced when B16F10 murine melanoma cells were injected with Sphk1-/- dermal fibroblasts 
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compared with WT fibroblasts.  15-20% of WT mice inoculated with B16F10 murine melanoma 
cells with WT fibroblasts developed lung metastasis, while 2.5% of the mice developed 
metastasis when Sphk1-/- fibroblasts were used.  The number of lung metastases was four times 
higher in mice implanted with B16F10 murine melanoma cells with WT fibroblasts compared 
with animals coinjected with Sphk1-/- fibroblasts.  Therefore, melanoma invasiveness is critically 
dependent upon S1P derived from fibroblast over-expressing SPHK1.  Consistent with these 
observations, S1P1 signalling in myeloid cells activates fibroblasts in distant organs and 
promotes the formation of a pre-metastatic niche8.  S1P lyase (SGPL1), the enzyme that 
catalyses the degradation of S1P, is also down-regulated in metastatic and invasive melanoma 
cells and this is likely to enhance S1P accumulation as a consequence of the BRAF-dependent 
up-regulation of SPHK1 in these cells.  Moreover, SGPL1 silencing in fibroblasts increases 
melanoma cell migration3. 
 
There are many thought provoking questions raised by the elegant study of Albinet et al.3.  First, 
it is unclear why S1P formed from SPHK1 in the melanoma cells does not act in an autocrine 
manner to stimulate melanoma migration.  The authors plausibly argue that S1P3 expression 
levels are not sufficiently high to promote migration, and that S1P released from the 
myofibroblast induces up-regulation of S1P3 expression in the melanoma cells to confer 
sensitivity to migration.  However, it is possible that S1P released from melanoma cells is not 
accessible to melanoma S1P3 receptors, especially if the S1P transporters are positioned close to 
a melanoma-fibroblast contact, where S1P has immediate access to fibroblast S1P receptors.  It is 
therefore important to determine whether S1P3 is the principle receptor mediating differentiation 
of fibroblasts into myofibroblasts or whether SPHK1 promotes the release from melanoma cells 
of alternative fibrotic factors, such as TGFE.  This would also provide an explanation for the lack 
of a direct effect of melanoma SPHK1 on migration.  
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Interestingly, we have shown that S1P promotes translocation of SPHK1 to the plasma-
membrane of MCF-7 breast cancer cells via an S1P3-dependent mechanism9.  In addition, siRNA 
knockdown of SPHK1 reduces S1P3 expression in these cells and this results in reduced 
S1P/S1P3-stimulated ERK-1/2 activation and abrogated migration of MCF-7 cells9.  Therefore, 
SPHK1 regulates responsiveness of these cancer cells by fine-tuning the expression level of 
S1P3.  It is possible that a similar ‘sensor’ mechanism operates between TAF and melanoma cells 
regulated by TAF released S1P and melanoma SPHK1.  This might produce a positive 
amplification loop of S1P3-mediated invasive signalling in the melanoma cell.  It would be 
interesting to establish the effect conditioned medium from differentiated fibroblasts on the 
migration of melanoma cells in which SPHK1 has been silenced.   
 
Second, the studies of Albinet et al.3 raise the question as to whether the communication between 
TAF and melanoma cells is therapeutically exploitable.  Clearly, anti-S1P immunotherapy might 
sequester S1P released from both TAFs and melanoma cells to disrupt the communication, 
although this requires formal testing.  Further consideration of the effect of depleting systemic 
S1P on immune surveillance is also required.  S1P3 antagonists might also be useful in 
preventing TAF-derived S1P driven melanoma invasiveness.  Finally, SPHK1 is a major 
therapeutic target.  We have shown that SPHK inhibitors, such as SKi (2-(p-hydroxyanilino)-4-
(p-chlorophenyl)thiazole) and FTY720 induce the ubiquitin-proteasomal degradation of SK1 in 
androgen-sensitive prostate cancer and MCF-7 breast cancer cells.  This results in an increase 
ceramide levels in androgen-sensitive prostate cancer cells which induces apoptosis10.  Liang and 
colleagues have also demonstrated that FTY720 reduces colitis-induced cancer via down-
regulation of SPHK1 expression that eliminates a malicious amplification loop involving 
SPHK1/S1P1 and STAT3/IL-6 formation11.  However, an N-terminal variant of SPHK1 (termed 
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SPHK1B) in androgen-independent prostate cancer cells evades the proteasome in response to 
SPHK1 inhibitors and this confers resistance to apoptosis10.  In addition, a novel SPHK1 
inhibitor, PF-543 with nM potency fails to induce apoptosis of certain cancer cells, although this 
compound does not increase ceramide levels indicating that it might modulate additional off-
targets that neutralise the effect of SPHK1 inhibition12.  Therefore, in certain cancer cells, the N-
terminal variant of SPHK1 might confer resistance to SPHK1 inhibitors.  The question then is 
whether SPHK1 in fibroblasts can also confer resistance to these inhibitors.  If this is not the 
case, then such inhibitors could potentially ablate communication between fibroblasts and 
melanoma cells to prevent metastasis. Indeed, chemoresistance is generally more prominent in 
cancer cells and the link with fibroblasts provides a new opportunity to indirectly attack 
melanoma. Therefore, the ground breaking studies of Albinet et al.3 provide substantial impetus 
to the development of anti-S1P therapeutics in cancer. 
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Fig. 1 Schematic showing the dual role of SPHK1 in regulating the interaction between 
melanoma cells and tumour associated fibroblasts which promotes metastasis.  The 
melanoma cell releases S1P/fibrotic factors under the regulatory control of SPHK1 (expression 
of which is regulated by BRAF) and this promote fibroblast/myofibroblast transition.  The 
SPHK1 in myofibroblasts then produces S1P which is released to bind to S1P3 receptors on the 
melanoma cell to promote dissemination (metastasis) of the cancer.  Therefore, SPHK1 performs 
a dual function and is a viable novel target for therapeutic intervention in melanoma. 
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